Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
Oncopeptides AB
AB
Active
Org 5565966438
Luntmakargatan 46, 111 37
Stockholm
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2000 · 25 years old
20-49 employees
Overvåg
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Oncopeptides AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
28M
56M
85M
113M
0M
2020
98M
2021
1M
2022
11M
2023
32M
2024
EBITDA
SEK millions
278M
-292M
-861M
-1431M
-2000M
-1600M
2020
-1410M
+12%
2021
-353M
+75%
2022
-252M
+29%
2023
222M
+188%
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
0
97 577
559
10 890
31 648
Staff expenses
—
—
—
—
—
EBITDA
−1 599 994
−1 409 814
−352 924
−252 188
222 334
Depreciation & amort.
—
—
—
—
—
EBIT
−1 599 994
−1 409 814
−352 924
−252 188
222 334
Net financials
358
−38 088
28 824
−9
−3 694
Profit before tax
−1 599 620
−1 428 539
−324 799
−253 940
184 577
Tax
−0
−0
−0
−0
−0
Net profit
−1 599 620
−1 428 539
−324 799
−253 940
184 577
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
844 953
363 495
357 705
221 780
760 233
Equity
569 528
204 653
302 610
60 169
527 502
Long-term debt
0
0
0
116 996
126 004
Short-term debt
220 024
158 783
53 280
44 615
106 727
Total debt
220 024
158 783
53 280
161 611
232 731
Financial ratios
5-year trend
EBITDA-margin
702.5%
This company
15.8%
Market median
+4346% vs market
2020
2024
Soliditetsgrad
69.4%
This company
38.2%
Market median
+82% vs market
2020
2024
Egenkapitalforrentning
35.0%
This company
18.4%
Market median
+90% vs market
2020
2024
Nettoresultatgrad
583.2%
This company
8.1%
Market median
+7100% vs market
2020
2024
Aktivomsætning
0.04×
This company
1.12×
Market median
-96% vs market
2020
2024
Gæld/egenkapital
0.44×
This company
0.62×
Market median
+29% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Oncopeptides AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
